Management ChangeJun 29, 2026, 07:31 AM
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
AI Summary
Xilio Therapeutics, Inc. announced the appointment of Ben Harshbarger as its new chief legal officer. Mr. Harshbarger brings over 20 years of executive leadership and legal expertise within the biopharmaceutical industry, having previously served as chief legal officer at Astria Therapeutics, Inc. and held senior legal roles at other companies. CEO René Russo stated that Harshbarger's experience will be crucial as Xilio advances its pipeline of next-generation, multi-specific immuno-oncology therapies.
Key Highlights
- Ben Harshbarger appointed Chief Legal Officer of Xilio Therapeutics.
- He brings over 20 years of legal and executive experience in biopharmaceutical industry.
- Previously served as Chief Legal Officer at Astria Therapeutics until its acquisition.
- Held roles at Novelion Therapeutics, Aegerion Pharmaceuticals, Cubist, ViaCell, and Biogen.
- CEO René Russo highlighted his experience for advancing Xilio's pipeline.
Price Impact
More from XLO